These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
396 related articles for article (PubMed ID: 29356626)
1. Not Everyone Fits the Mold: Intratumor and Intertumor Heterogeneity and Innovative Cancer Drug Design and Development. Dzobo K; Senthebane DA; Thomford NE; Rowe A; Dandara C; Parker MI OMICS; 2018 Jan; 22(1):17-34. PubMed ID: 29356626 [TBL] [Abstract][Full Text] [Related]
2. Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic. Dzobo K OMICS; 2020 Apr; 24(4):175-179. PubMed ID: 32176591 [TBL] [Abstract][Full Text] [Related]
3. Role of the Immune Component of Tumor Microenvironment in the Efficiency of Cancer Treatment: Perspectives for the Personalized Therapy. Stakheyeva M; Riabov V; Mitrofanova I; Litviakov N; Choynzonov E; Cherdyntseva N; Kzhyshkowska J Curr Pharm Des; 2017; 23(32):4807-4826. PubMed ID: 28714406 [TBL] [Abstract][Full Text] [Related]
4. Cell Culture System for Analysis of Genetic Heterogeneity Within Hepatocellular Carcinomas and Response to Pharmacologic Agents. Gao Q; Wang ZC; Duan M; Lin YH; Zhou XY; Worthley DL; Wang XY; Niu G; Xia Y; Deng M; Liu LZ; Shi JY; Yang LX; Zhang S; Ding ZB; Zhou J; Liang CM; Cao Y; Xiong L; Xi R; Shi YY; Fan J Gastroenterology; 2017 Jan; 152(1):232-242.e4. PubMed ID: 27639803 [TBL] [Abstract][Full Text] [Related]
6. Drivers of dynamic intratumor heterogeneity and phenotypic plasticity. Biswas A; De S Am J Physiol Cell Physiol; 2021 May; 320(5):C750-C760. PubMed ID: 33657326 [TBL] [Abstract][Full Text] [Related]
7. A Practical Approach to Tumor Heterogeneity in Clinical Research and Diagnostics. Stanta G; Bonin S Pathobiology; 2018; 85(1-2):7-17. PubMed ID: 28750401 [TBL] [Abstract][Full Text] [Related]
9. Intratumor Heterogeneity: Novel Approaches for Resolving Genomic Architecture and Clonal Evolution. Gupta RG; Somer RA Mol Cancer Res; 2017 Sep; 15(9):1127-1137. PubMed ID: 28596419 [TBL] [Abstract][Full Text] [Related]
10. Adapting clinical paradigms to the challenges of cancer clonal evolution. Murugaesu N; Chew SK; Swanton C Am J Pathol; 2013 Jun; 182(6):1962-71. PubMed ID: 23708210 [TBL] [Abstract][Full Text] [Related]
11. Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient-derived cancer cells. Saeed K; Ojamies P; Pellinen T; Eldfors S; Turkki R; Lundin J; Järvinen P; Nisen H; Taari K; Af Hällström TM; Rannikko A; Mirtti T; Kallioniemi O; Östling P Int J Cancer; 2019 Mar; 144(6):1356-1366. PubMed ID: 30125350 [TBL] [Abstract][Full Text] [Related]
13. Variability in the Solid Cancer Cell Population and Its Consequences for Cancer Diagnostics and Treatment. Brychtová V; Valík V; Vojtěšek B Klin Onkol; 2018; 31(Suppl 2):5-13. PubMed ID: 31023018 [TBL] [Abstract][Full Text] [Related]
14. Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity. Ketola K; Kaljunen H; Taavitsainen S; Kaarijärvi R; Järvelä E; Rodríguez-Martín B; Haase K; Woodcock DJ; Tubio J; Wedge DC; Nykter M; Bova GS Cancer Res; 2021 Oct; 81(19):4901-4909. PubMed ID: 34348967 [TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of breast cancer: The importance of interaction between different tumor cell populations. Januškevičienė I; Petrikaitė V Life Sci; 2019 Dec; 239():117009. PubMed ID: 31669239 [TBL] [Abstract][Full Text] [Related]
16. Tumour heterogeneity and resistance to cancer therapies. Dagogo-Jack I; Shaw AT Nat Rev Clin Oncol; 2018 Feb; 15(2):81-94. PubMed ID: 29115304 [TBL] [Abstract][Full Text] [Related]
17. Intratumor heterogeneity: origins, clinical significance and optimal strategies for cancer treatment. Mangano A; Lianos GD; Mangano A; Boni L; Dionigi G Future Oncol; 2015; 11(4):561-4. PubMed ID: 25686113 [No Abstract] [Full Text] [Related]
18. Intratumor Heterogeneity in Breast Cancer. Beca F; Polyak K Adv Exp Med Biol; 2016; 882():169-89. PubMed ID: 26987535 [TBL] [Abstract][Full Text] [Related]
19. Spatiotemporal diversification of intrapatient genomic clones and early drug development concepts realize the roadmap of precision cancer medicine. Roukos DH Drug Discov Today; 2017 Aug; 22(8):1148-1164. PubMed ID: 28400153 [TBL] [Abstract][Full Text] [Related]
20. Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma. Reinartz R; Wang S; Kebir S; Silver DJ; Wieland A; Zheng T; Küpper M; Rauschenbach L; Fimmers R; Shepherd TM; Trageser D; Till A; Schäfer N; Glas M; Hillmer AM; Cichon S; Smith AA; Pietsch T; Liu Y; Reynolds BA; Yachnis A; Pincus DW; Simon M; Brüstle O; Steindler DA; Scheffler B Clin Cancer Res; 2017 Jan; 23(2):562-574. PubMed ID: 27521447 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]